期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

短程大剂量瑞舒伐他汀对急性冠脉综合征患者血糖和血脂代谢的影响 被引量：8

下载PDF
导出
摘要 目的观察急性冠脉综合征患者短程服用大剂量瑞舒伐他汀后对血糖和血脂代谢的影响。方法将82例急性冠脉综合征患者随机分为瑞舒伐他汀(20 mg/d)大剂量组和瑞舒伐他汀(10 mg/d)常规剂量组,每组41例。观察4周后两组空腹血糖(FBG)、餐后2 h血糖(PBG)、糖化血红蛋白(Hb A1c)、血脂、高敏C反应蛋白(hs-CRP)水平和不良反应发生率等指标变化。结果治疗4周后两组低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)均有明显降低(P<0.05),且大剂量组下降程度更低,大剂量组治疗后PBG水平较治疗前明显升高(P<0.05),两组均未发现严重不良反应。结论短程大剂量瑞舒伐他汀能显著降低急性冠脉综合征患者血脂、hs-CRP水平,同时可能会升高餐后2 h血糖水平。
作者 蒋建东 赵祥海 陈燕春 杨松
机构地区 江苏省宜兴市人民医院
出处 《中西医结合心脑血管病杂志》 2015年第10期1197-1198,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 急性冠脉综合征 瑞舒伐他汀 血糖代谢 血脂
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献14

  • 1Ridker PM,MacFadyen 3, Libby P, et al . Relation of baseline high - sensitivity C reactive protein level to cardiovascular out- comes with rosuvastatin in the justification for use of statins in Prevention:An Intervention Trial Evaluating Rosuvastatin (JUPI TER> [J] .Am J Cardiol, 201,106( 2) : 204 - 209.
  • 2Jones PH, Davidson MH, Stein EA, et al. Comparison of the effi- cacy and safety of rosuvastatin versus atorvastatin,simvastatin, and pravastatin across doses(STELLAR Trial) [J]. Am J Cardi- ol,2003,93(2) : 152 - 160.
  • 3Schuster H, Barter P J, Stender S, et al. Effects of switching st- atins on achievement of lipid goals, Measuring Effective Reduc tions in Cholesterol Using Rosuvastatin Therapy(MERCURY I) study[J]. Am Heart J, 2004,147(4) : 705 - 712.
  • 4Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hyperchol- esterolemia and a high risk of coronaty heart disease:A random- ized, controlled trial[J]. Am Heart J, 2004, 148( 1 ) : e4.
  • 5Yun KH,Oh SK,Rhee S J, et al .12 month follow up results of high dose rosuvastatin loading before percutaneous coronary in tervention in patients with acute coronary syndrome [J]. int J Cardioh 2011,146( 1), 68- 72.
  • 6Yun KH,Jeong MH,Oh SK.The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J].lnt J Cardioh 2009, 137(3):246- 251.
  • 7Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes:A meta nalysis [J]. Dia- betes Care,2009,32(10) :1924- 1929.
  • 8Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:A collaborative meta- analysis of randomized statin tri als[J].Lancet, 2010,375(9716) ; 735 - 742.
  • 9Preiss D,Seshasai SR,Welsh P, et al. Risk of incident diabetes with intensive - dose compared with moderate - dose statin ther apy: A meta - analysisE J]. JAMA, 2011,305(24) : 2556 - 2564.
  • 10Kuznetsova MA,Vaulin NA, Masenko VP, Gratsianski NA.Non- ST elevation acute coronary syndrome.Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and mark ers of inflammation[J]. Kardiologiia, 2010, 50(2) : 21 - 25.

同被引文献81

  • 1无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量：2082
  • 2Encinar JA,Fernández BG,Galiano IV,et al.In silico approach for the discovery of new PPARγmodulators among plant-derived polyphenols[J].Drug Des Devel Ther,2015,4(9):5877-5895.
  • 3T a n X C,C h u a K H,R a v i s h a n k a r R a m M,e t al.Monoterpenes:Novel insights into their biological effects and roles on glucose uptake and lipid metabolism in 3T3-L1 adipocytes[J].Food Chem,2016,1(196):242-250.
  • 4Tang Y,Peng Y,Liu J,et al.Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APPSWE/PSEN1d E9 mouse model of Alzheimer's disease[J].J Neurochem,2015,11(18):78-81.
  • 5Cox DJ,Taylor AG,Singh H,et al.Glycemic load,exercise,and monitoring blood glucose(GEM):A paradigm shift in the treatment of type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2015,21(15):422-424.
  • 6Janghorbani M,Papi B,Amini M.Current status of glucose,blood pressure and lipid management in type 2diabetes clinic attendees in Isfahan,Iran[J].J Diabetes Investig,2015,6(6):716-725.
  • 7Lu J,Yu H,Mo Y,et al.Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2Diabetes[J].PLo S One,2015,10(11):207-209.
  • 8郑春美,张华芳.瑞舒伐他汀的不良反应及应对措施[J].中国现代应用药学,2010,27(2):115-117. 被引量：11
  • 9严励,王川.糖尿病血脂异常研究新进展[J].中华内分泌代谢杂志,2012,28(9):704-709. 被引量：18
  • 10李忠华.他汀类药物应用于社区心血管疾病二级预防的依从性分析[J].实用医学杂志,2013,29(7):1156-1158. 被引量：30

二级引证文献44

中西医结合心脑血管病杂志
2015年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部